Clinical Features and Risk Factors of Active Tuberculosis in Patients with Behçet’s Disease
Table 1
Past medical history and medication of BD patients with and without ATB.
BD with ATB ()
BD without ATB ()
Sex (male, %)
13 (61.90%)
35 (50.72%)
0.369
Age ()
0.450
Past medical history
Previous contact with ATB patients (%)
3 (14.29%)
2 (2.90%)
0.081
Previous prophylactic treatment of TB (%)
1 (4.76%)
3 (4.35%)
1.000
Evidence of PTB a (%)
13 (61.90%)
17 (24.64%)
0.002
Previous treatment of BD
Glucocorticoid
Maximal dosage (mg/d, median, IQR)b
0 (0, 50)
25 (0, 60)
0.093
Duration (months, median, IQR)
0 (0, 3.5)
3 (0, 13)
0.028
Biologics
Infliximab (%)
2 (9.52%)
2 (2.90%)
0.231
Other TNF-α inhibitors (%)
2 (9.52%)
3 (4.35%)
0.587
Immunosuppressant
CTX (%)
5 (23.81%)
11 (15.94%)
0.515
CsA (%)
0 (0%)
10 (14.49%)
0.109
MTX (%)
1 (4.76%)
3 (4.35%)
1.000
FK506 (%)
1 (4.76%)
2 (2.90%)
0.554
AZA (%)
2 (9.52%)
5 (7.25%)
0.663
Current treatment of BDc
Glucocorticoid dosage (mg/d, median, IQR)b
0 (0, 15)
5 (0, 32.5)
0.177
Biologics
Infliximab (%)
0 (0%)
2 (2.90%)
1.000
Other TNF-α inhibitor (%)
1 (4.76%)
0 (0%)
0.233
Immunosuppressant
CTX (%)
1 (4.76%)
11 (15.94%)
0.281
CsA (%)
1 (4.76%)
7 (10.14%)
0.675
MTX (%)
0 (0%)
0 (0%)
—
FK506 (%)
1 (4.76%)
1 (1.45%)
0.414
AZA (%)
1 (4.76%)
1 (1.45%)
0.414
aEvidence of PTB includes past history of TB infection and radiological features indicating PTB in chest CT. bAll forms of glucocorticoid were converted to the equivalent dosage of prednisone. cCurrent use of immunosuppressant and biologics indicates continuous use of the drug for 3 months before hospitalization, and the dosage of glucocorticoid records the maximal dose of glucocorticoid within 2 weeks before hospitalization. TNF-α: tumor necrosis factor-α; CTX: cyclophosphamide; CsA: ciclosporin A; MTX: methotrexate; FK506: tacrolimus; AZA: azathioprine; LEF: leflunomide; MMF: mycophenolate mofetilhs.
